SGLT2 and GLP-1 Combination Therapy Reduces Cardiorenal Risks in Type 2 Diabetes
Recent research indicates that combining sodium-glucose cotransporter 2 (SGLT2) inhibitors with glucagon-like peptide-1 receptor agonists (GLP-1RAs) provides superior cardiorenal protection for patients with type 2 diabetes compared to either treatment alone. While clinical outcomes vary depending on the specific health markers being measured, recent evidence suggests this combination therapy significantly reduces risks associated with cardiovascular … Read more